top of page

ANALLISA

PHASE II STUDY TO ASSESS THE EFFICACY OF NIRAPARIB RECHALLENGE AFTER SURGERY IN OVARIAN CANCER PATIENTS WITH OLIGOMETASTATIC PROGRESSION (THE ANALLISA STUDY)

Endometrioid Ovarian Cancer

II

30

9

Spain

Recruitment

CLINICAL TRIAL DETAILS

THE PRIMARY OBJECTIVE IS TO EVALUATE PROGRESSION-FREE SURVIVAL (PFS) OF NIRAPARIB RECHALLENGE IN OC PATIENTS WITH OMP AND NO RESIDUAL DISEASE AFTER SECONDARY CYTOREDUCTIVE SURGERY.


ANALLISA AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

TRIAL RESUME

home_fondo_you_barra.jpg

Dr. Alfonso Cortés, PI of the ANALLISA trial

ANALLISA.png

ANALLISA SITES

home_fondo_you_barra.jpg
home_fondo_you_barra.jpg

SPAIN

Hospital Universitario Ramón y Cajal

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario Jaén

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario La Paz

home_fondo_you_barra.jpg

SPAIN

Vall d’Hebron Institute of Oncology

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario San Juan de Reus

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario 12 de Octubre

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario de A Coruña (CHUAC)

home_fondo_you_barra.jpg

SPAIN

Hospital Universitario Virgen Macarena

home_fondo_you_barra.jpg

SPAIN

Hospital Arnau de Vilanova de Valencia

bottom of page